Synopsis
0
EU WC
0
VMF
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CEP/COS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Kirsch Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Parenteral
Solubilizers
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Regulatory FDF Prices
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Annual Reports
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
35
PharmaCompass offers a list of Carteolol API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Carteolol manufacturer or Carteolol supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Carteolol manufacturer or Carteolol supplier.
A Carteolol manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Carteolol, including repackagers and relabelers. The FDA regulates Carteolol manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Carteolol API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Carteolol manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Carteolol supplier is an individual or a company that provides Carteolol active pharmaceutical ingredient (API) or Carteolol finished formulations upon request. The Carteolol suppliers may include Carteolol API manufacturers, exporters, distributors and traders.
click here to find a list of Carteolol suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Carteolol DMF (Drug Master File) is a document detailing the whole manufacturing process of Carteolol active pharmaceutical ingredient (API) in detail. Different forms of Carteolol DMFs exist exist since differing nations have different regulations, such as Carteolol USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Carteolol DMF submitted to regulatory agencies in the US is known as a USDMF. Carteolol USDMF includes data on Carteolol's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Carteolol USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Carteolol suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Carteolol Drug Master File in Japan (Carteolol JDMF) empowers Carteolol API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Carteolol JDMF during the approval evaluation for pharmaceutical products. At the time of Carteolol JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Carteolol suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Carteolol Drug Master File in Korea (Carteolol KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Carteolol. The MFDS reviews the Carteolol KDMF as part of the drug registration process and uses the information provided in the Carteolol KDMF to evaluate the safety and efficacy of the drug.
After submitting a Carteolol KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Carteolol API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Carteolol suppliers with KDMF on PharmaCompass.
A Carteolol CEP of the European Pharmacopoeia monograph is often referred to as a Carteolol Certificate of Suitability (COS). The purpose of a Carteolol CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Carteolol EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Carteolol to their clients by showing that a Carteolol CEP has been issued for it. The manufacturer submits a Carteolol CEP (COS) as part of the market authorization procedure, and it takes on the role of a Carteolol CEP holder for the record. Additionally, the data presented in the Carteolol CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Carteolol DMF.
A Carteolol CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Carteolol CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Carteolol suppliers with CEP (COS) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Carteolol as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Carteolol API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Carteolol as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Carteolol and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Carteolol NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Carteolol suppliers with NDC on PharmaCompass.
Carteolol Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Carteolol GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Carteolol GMP manufacturer or Carteolol GMP API supplier for your needs.
A Carteolol CoA (Certificate of Analysis) is a formal document that attests to Carteolol's compliance with Carteolol specifications and serves as a tool for batch-level quality control.
Carteolol CoA mostly includes findings from lab analyses of a specific batch. For each Carteolol CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Carteolol may be tested according to a variety of international standards, such as European Pharmacopoeia (Carteolol EP), Carteolol JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Carteolol USP).
Comment (3)
